



We Can't Afford to Say No To Biogenerics

Gary Heimberg
Vice President of Federal Affairs
Generic Pharmaceutical Association

COST

- TOTAL U.S. SPENDING ON BIOLOGICS ROSE 21% IN 2006
- SPENDING FOR BIOTECH DRUGS IN THE U.S. IS EXPECTED TO HIT \$90 BILLION IN 2009.



COMPETITION

- WILL REDUCE COSTS AS LOWER PRICED GENERICS COMPETE IN THE MARKETPLACE
- WILL SPUR INNOVATION AS BRAND COMPANIES SEEK TO DEVELOP NEW MEDICINES



CHOICE

- U.S. PATIENTS SHOULD HAVE ACCESS TO LOWER COST GENERIC VERSIONS OF BRANDED BIOTECH MEDICINES
- FDA WOULD APPLY THE SAME RIGOROUS APPROVAL PROCESS TO GENERICS

CONCLUSION

- THE DEBATE IS NO LONGER “IF,” BUT “WHEN”
- GENERIC COMPANIES HAVE MADE INVESTMENTS AND ARE READY TO ROLL
- CONGRESS HOLDS THE KEY TO OPENING THE DOOR FOR SAVINGS



Thank you!

Gary Heimberg
Vice President of Federal Affairs
Generic Pharmaceutical Association
703-647-2480
gheimberg@gphaonline.org